Trevi Therapeutics, a biopharmaceutical firm in the midst of clinical testing, is putting its focus squarely on the development and ultimate distribution of Haduvio. This drug is designed to provide relief for serious coughs that target both the central and peripheral nervous systems, and is being developed as an extended-release formula of nalbuphine. Currently, Haduvio is in phase 2b/3 clinical trials and is being tested as a potential treatment for chronic pruritus and chronic cough in patients with idiopathic pulmonary fibrosis. Trevi Therapeutics has a licensing agreement with Endo Pharmaceuticals Inc. to develop and distribute treatment products that incorporate nalbuphine hydrochloride in any form. The company was founded in 2011 and is headquartered in New Haven, Connecticut.